Pirtobrutinib (LOXO-305)
Drug timelines are a Plus or Pro feature.
8 regulatory and trial events tracked for Pirtobrutinib (LOXO-305), covering 2025-01-13 to 2026-04-23. Get the full timeline:
Most recent: Clinical Trial Update: Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients [Phase 2]